UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
January 7, 2019

Twist Bioscience Corporation
(Exact name of registrant as specified in its charter)

Delaware	**001-38720**	**46-205888**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(I. R. S. Employer Identification No.)**

455 Mission Bay Boulevard South
Suite 545
San Francisco, CA 94158
(Address of principal executive offices, including ZIP code)

(800) 719-0671
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 7.01 Regulation FD Disclosure.

Twist Bioscience Corporation (the "***Company***") is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of a PowerPoint presentation (the "***Presentation***"), to be used by the Company at various meetings with certain investors. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later company filing or other means. A copy of the Presentation is furnished herewith as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.

The information contained in the Presentation should be considered in the context of the Company's filings with the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise from time to time. The Presentation speaks as of the date of this Current Report on Form 8-K. By furnishing this Current Report on Form 8-K and furnishing the Presentation, the Company makes no admission as to the materiality of any information in this Current Report on Form 8-K, including without limitation the Presentation. The Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement in the Presentation is based.

The information furnished in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Presentation slide deck dated January 2019.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 7, 2019

Twist Bioscience Corporation

/s/ Mark Daniels

Mark Daniels
Senior Vice President, Chief Legal Officer, Chief Ethics and Compliance Officer, and Secretary

Exhibit 99.1

TWIST BIOSCIENCE

Powering the Synthetic Biology and Genomics Revolutions

/ 37th Annual JPM HC conference

/ January 2019

/ TwistBioscience

/ #WeMakeDNA

Safe Harbor Statement

This presentation contains forward-looking statements. In particular, statements regarding future economic performance, finances, and expectations and objectives of management constitute forward-looking statements. Forward-looking statements can be identified by the fact that they do not relate strictly to historical facts and generally contain words such as "believes," "expects," "may," "will," "should," "seeks," "approximately," "intends," "plans," "estimates," "anticipates," and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters. Although the forward-looking statements contained in this presentation are based upon information available at the time the statements are made and reflect management's good faith beliefs, forward-looking statements inherently involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements to differ materially from anticipated future results. Important factors that could cause actual results to differ materially from expectations include, among others: our estimates of the size of our market opportunity; our expectations regarding our ability to increase gene production, reduce turnaround times and drive cost reductions for our customers; and our ability to enter new markets. You should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

By attending or receiving this presentation you acknowledge that you will be solely responsible for your own assessment of the market and our market position and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of our business.

Writing Synthetic DNA on Silicon Platform

Fueling the Industrialization of Synthetic Biology

KEY ADVANTAGES OF WRITING DNA ON SILICON

MINIATURIZATION
10^{3-6} less volume of required reagents

THROUGHPUT
20M oligos/month

LOW COST
Driving adoption and new applications

VERSATILE PLATFORM
Broad applications

Our Versatile DNA Synthesis Platform Has Broad Applications

Twist's versatile DNA synthesis platform has broad application across many enabling synthetic biology products, and **we are just beginning…**

Our Strategy

SYNTHETIC BIOLOGY: GENE SYNTHESIS → GENOMICS: TARGETED NGS → OPEN NEW MARKETS

Near-term strategic priorities | *Long-term initiatives*

- Lead the Buyer market
- Convert Makers into Buyers



Twist's advantages in…

Exome
- Performance
- Customization
- Full kit

Custom
- Turnaround time
- Affordable pilot and scaling
- NGS QC on all probes

- Augment our product offering to meet the growing needs of our existing and potential new customers
- Expand into adjacent addressable markets
- Leverage our platform and industry partnerships to create new market opportunities for our products


DRUG DISCOVERY


DATA STORAGE

*Source: Markets and Market Molecular Biology (2014) / BCC Research (2017)

Twist Bioscience Pipeline

MARKET OPPORTUNITIES	EXPLORATION	PROOF OF CONCEPT	BETA	COMMERCIAL	NEXT STEPS
Synthetic Biology: Synthetic Genes, DNA Libraries and Oligo Pools[1]					• Continue to drive growth, add market share • 5kb genes, Twist API • NPI roadmap
Genomics: Targeted NGS[2]					• Continue converting NGS pilot accounts to production • Launch NGS e-commerce platform • ISO 13485 certification • Backend in China
Biological Drug Discovery and Development[3]					• POC GPCR library and Ab optimization solution • Establish partnerships
Digital Data Storage in DNA					• Continue to develop partnerships to explore digital data storage in DNA

[1] Products addressing this market include clonal, non-clonal genes (gene fragments), oligo pools and DNA libraries
[2] Products addressing this market include NGS exome capture and NGS custom capture
[3] Products addressing this market include custom DNA libraries, our proprietary GPCR-targeting antibody library and our antibody optimization solution

TWIST'S PLATFROM TECHNOLOGY ADDRESSES

Multiple Large Market Opportunities

$1.3B
SYNTHETIC BIOLOGY

- Competitive Turnaround Time
- Lower Cost
- High Throughput
- High Quality

$0.5B
GENOMICS: TARGETED NGS

- Fast Customization
- Performance
- Full Kit
- High Quality

SHORT TERM GOAL
Grow Revenue

Source: BCC Report (2017), Markets and Markets (2014) DeciBio (2015)

LARGE MARKET OPPORTUNITIES

LARGE MARKET
DRUG DISCOVERY/ DEVELOPMENT

- High Quality Diversity Hits / Leads
- Shorter Time and Cost from Target to IND

MID TERM GOAL
Develop novel therapeutics

$35B+
DATA STORAGE

- Permanence
- Density
- Ease of Copying
- Universal Format

LONG TERM GOAL
Enter technology market

Source: LDC Market Analysis, LTO Program Technology Provider Companies

Synthetic Biology is a Rapidly Growing $4B Opportunity

NEEDS	NEW APPLICATIONS FOR SYNTHETIC DNA
Healthcare • Better drug development tools to lessen time and lower costs • More effective diagnostic tools for DNA extraction to lower costs (i.e. NGS)	• Antibodies / TCR • Vaccines • Immuno and Cancer Therapies • Small Molecule Drug Manufacture
Industrial • Increased population growth impacting the sustainability of finite resources • Industrial production to address the needs of civilization	• Specialty Chemicals • Advanced Property Materials
Agriculture • Global population growing with decrease in per capita arable land • Food security and increased nutrition	• Self-fertilizing crops • Oil-Free Fertilizers • Drought Solutions • New Disease Protection

We need a new type of DNA supplier to meet demand

Source: BCC Research

Gene Synthesis Market: Buyers and Makers

$1.3B / Year

Large Scale, Commercial Users

Value: Speed, Throughput and Quality

Can't get what I need



Small Scale, Academic Users

Price-Sensitive

I Hate Cloning

Source: BCC Report (2017), Markets and Markets Molecular Biology (2014)

Rewriting DNA with the Power of Silicon

96 WELL PLATE
makes 1 gene

TWIST SILICON PLATFORM
can make 9,600 gene

Developing Game-Changing Throughput and Cost through Quality and Speed at Scale

TWIST VALUE PROPOSITION

Key Advantages

- HIGH QUALITY
- UNIQUE CUSTOMER EXPERIENCE
- LOWER COST
- UNPRECEDENTED THROUGHPUT / SCALE
- CONSISTENT RELABILITY
- COMPETITIVE TURNAROUND TIME
- COMPREHENSIVE PRODUCT OFFERING

A Unique Way to Order your DNA Online …



E-Commerce is Enabling Capture of Long Tail

E-COMMERCE IMPACT
Q1-18 VS. Q1-19*

45% lower PO size as we reach long tail

3.5x more orders



*unaudited, ex-Ginkgo, synbio

Now Available:

5kb Genes

at disruptive price

- Increase serviceable market
- Enable maker to buyer conversion

3.2kb → 5kb

API

- Seamless integration
- Increase service stickiness

Disease Diagnostics

Targeted NGS is enabling reading of patient's and/or pathogen's DNA to inform precision or personalized medical treatment

- Reduced sequencing cost per sample
- Faster time to results
- Increased sensitivity / complete coverage of difficult regions

Targeted NGS value chain



Targeted NGS – Strong Value Proposition

PERFORMANCE / COST
- High Uniformity
- Low Sequencing Costs

CUSTOMIZATION
- 2-3 Weeks Design to Production
- On Custom and Exome Panels

FULL KIT
- All Consumables From One Provider

NGS Conversion – Pilot to Production Pipeline



- Pilot to production cycle typically requires 9 to 18 months
- First Twist customers moved to production Q4 2018
- Capturing more orders and increasing average order size as customer scale-up:

Shipped to over 100 customers in Q1-FY19*	**Out of 74 major potential customers: 17 have adopted Twist in their production**

*unaudited

Strong Orders Growth



Customer Growth



Revenue Growth FY16-19



*Twist FY19 Revenue Guidance: $46M-$48M

TWIST'S PLATFROM EXTENDS TO

Other Growth Verticals

$1.3B
SYNTHETIC BIOLOGY

- Competitive Turnaround Time
- Lower Cost
- High Throughput
- High Quality

$0.5B
GENOMICS: TARGETED NGS

- Fast Customization
- Performance
- Full Kit
- High Quality

SHORT TERM GOAL
Grow Revenue

Source: BCC Report (2017), Markets and Markets (2014) DeciBio (2015)



LARGE MARKET
DRUG DISCOVERY/ DEVELOPMENT

- High Quality Diversity Hits / Leads
- Shorter Time and Cost from Target to IND

MID TERM GOAL
Develop novel therapeutics

$35B+
DATA STORAGE

- Permanence
- Density
- Ease of Copying
- Universal Format

LONG TERM GOAL
Enter technology market

Source: LDC Market Analysis, LTO Program Technology Provider Companies

Novel Protein Libraries for Drug Discovery

To Enable Efficiency in Drug Discovery

From Needle in a Haystack

- Random diversity
- Biased representation
- >99% inefficiency
- Lengthy optimization cycle
- Expensive process

To Stack of Needles

- Explicit
- Even representation
- Human repertoire based
- Fast
- Affordable

Precise Introduction of Variants, Diversity that Enables Screening Efficiency



Gene Synthesis

Single Site

Multi-Site

Stretch

Multi-Domain

Expanding Drug Discovery Capabilities

Enables Tackling Bio-Betters and Hard-to-Drug Targets



Twist Biopharma Proof-of-Concept: GPCR Library and Bio-Better

GPCR: Target 1





A Panel of Cell Target(+) IgGs Identified

Of These Cell Binding IgGs, several are Antagonists

Bio-Better: PDL1 inhibitor



Parental Antibody (>500 nM) **Optimized Antibody (570 pM)**



TWIST'S PLATFROM EXTENDS TO

Other Growth Verticals

$1.3B
SYNTHETIC BIOLOGY

- Competitive Turnaround Time
- Lower Cost
- High Throughput
- High Quality

$0.5B
GENOMICS: TARGETED NGS

- Fast Customization
- Performance
- Full Kit
- High Quality

SHORT TERM GOAL
Grow Revenue

Source: BCC Report (2017), Markets and Markets (2014) DeciBio (2015)



LARGE MARKET
DRUG DISCOVERY/ DEVELOPMENT

- High Quality Diversity Hits / Leads
- Shorter Time and Cost from Target to IND

MID TERM GOAL
Develop novel therapeutics

$35B+
DATA STORAGE

- Permanence
- Density
- Ease of Copying
- Universal Format

LONG TERM GOAL
Enter technology market

Source: LDC Market Analysis, LTO Program Technology Provider Companies

DNA: Nature's Choice for Data Storage

MAN-MADE,
NOT PERMANENT



STABLE FOR 1000s of YEARS

20,000
Years ago

Sequencing the nuclear genome of the extinct woolly mammoth

Webb Miller, Daniela I. Drautz, Aakrosh Ratan, Barbara Pusey, Ji Qi, Arthur M. Lesk, Lynn P. Tomsho, Michael D. Packard, Fangqing Zhao, Andrei Sher, Alexei Tikhonov, Brian Raney, Nick Patterson, Kerstin Lindblad-Toh, Eric S. Lander, James R. Knight, Gerard P. Irzyk, Karin M. Fredrikson, Timothy T. Harkins, Sharon Sheridan, Tom Pringle & Stephan C. Schuster

40,000
Years ago

A Draft Sequence of the Neandertal Genome

560,000 - 780,000
Years ago

Recalibrating *Equus* evolution using the genome sequence of an early Middle Pleistocene horse



Data Storage in DNA

1 Coding

00 → A
01 → G
10 → C
11 → T

2 Synthesis

3 Storage

4 Retrieval

5 Sequencing

6 Decoding

A → 00
G → 01
C → 10
T → 11

Permanence • Density • Random Access • Universal format

DNA Data Storage Trends and Projections

We believe new DNA technologies and cost efficiencies could surpass mature IT hardware solutions in 3–5 years



* DNA bases per byte for hard drive and tape shown at typical published encoding ranges from about 5:1 to 6.25:1

** All dotted lines represent extrapolations and assumes continued trajectory of historical trends, and that there will be continued decrease in price as technology improves.

*** Raw oligo pool cost extrapolation based on DARPA and another anticipated government-sponsored grant project objectives, both at specified time points

(1) www.genome.Gov (2) Bob Fontana, IBM Systems, Storage Media Overview, May 4,2016 (3) Bioeconomy Capital, Rob Carlson, January 20, 2018, www.synthesis.cc

Experienced Management Team

Emily LeProust, PhD
President, CEO, Co-founder
Agilent Technologies

Bill Banyai, PhD
COO, Co-founder
Complete Genomics

Bill Peck, PhD
CTO, Co-founder
Complete Genomics

Jim Thorburn
CFO
Televerde

Aaron Sato
CSO, Twist Pharma
LakePharma

Ray Tabibiazar
SVP Corporate Development
aravive BIOLOGICS
Twist Bioscience Corporation

Patrick Finn, PhD
VP Sales and Marketing
enzymatics

Patrick Weiss
VP Operations
operon molecules for life

Paula Green
VP Human Resources
QIAGEN

Mark Daniels
Chief Legal Officer, Chief Ethics and Compliance Officer, Secretary
BROADCOM

Strong Momentum and Milestones Achieved



Significant opportunities to drive further growth



Why Twist?



TWIST BIOSCIENCE